What is Newomics?
Newomics is at the forefront of developing advanced solutions for liquid chromatography-mass spectrometry (LC-MS), a critical technology in fields such as clinical diagnostics, drug development, and environmental monitoring. Their product portfolio, including the UniESI system and MEA chip, is engineered to enhance sensitivity and throughput, making complex analyses more accessible. The company's commitment to plug-and-play compatibility and robust performance positions it as a key player in the advancement of multiomics technologies, catering to a diverse clientele seeking precise and efficient analytical tools.
How much funding has Newomics raised?
Newomics has raised a total of $11.9M across 3 funding rounds:
Series A
$3.9M
Debt
$150K
Series B
$7.9M
Series A (2018): $3.9M with participation from Undisclosed
Debt (2020): $150K led by PPP
Series B (2020): $7.9M supported by MSA Capital, Berkeley Catalyst Fund, LDV Partners, and Photon Fund
Key Investors in Newomics
MSA Capital
MSA Capital is a global private equity and venture capital firm with over $1.5 billion under management, actively partnering with entrepreneurs to build leading, innovative companies that aim to deliver strong financial returns and positive social impacts.
Berkeley Catalyst Fund
Berkeley Catalyst Fund is a venture capital firm that provides benefits to entrepreneurial startups, focusing on fostering innovation and growth in early-stage companies.
LDV Partners
LDV Partners is dedicated to transforming innovative ideas into successful companies by collaborating closely with visionary founders, providing strategic insights and essential resources to foster growth in disruptive technologies.
What's next for Newomics?
With substantial enterprise-level backing and a recent strategic investment, Newomics is poised for accelerated expansion and innovation. The company's focus on high-performance LC-MS devices suggests a strategic push to capture greater market share in clinical mass spectrometry, metabolomics, and proteomics. Future developments are likely to center on further enhancing their product suite, expanding application areas, and potentially forging new partnerships to leverage their technology in emerging scientific and diagnostic fields. This capital infusion will be instrumental in scaling operations and solidifying their position as a leader in multiomics.
See full Newomics company page
